Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.53 |
| ▸ | KIF11 | P52732 | 5/20 | 0.52 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.50 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.48 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.48 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023134 | 0.98 | PDE3A (0.62) | PDE3AHSD17B10ARPDE3BKIF11 | |
| SCHEMBL7032407 | 0.86 | PDE3A (0.50) | PDE3AHSD17B10ARPDE3BCA12 | |
| SCHEMBL7026070 | 0.85 | KIF11 (0.55) | PDE3AKIF11CDK5CDK5R1ALDH1A1 | |
| SCHEMBL7029687 | 0.85 | PDE3A (0.55) | PDE3AHSD17B10PDE3BKIF11MEN1 | |
| SCHEMBL7024817 | 0.81 | PDE3A (0.46) | PDE3AHSD17B10ARPDE3BKIF11 | |
| SCHEMBL26133119 | 0.81 | PDE3A (0.46) | PDE3AHSD17B10ARKIF11CA12 | |
| SCHEMBL31296617 | 0.81 | PDE3A (0.46) | PDE3AHSD17B10ARKIF11CA12 | |
| SCHEMBL7029333 | 0.77 | DRD4 (0.55) | HSD17B10KIF11ALDH1A1MAPTKDM4E | |
| SCHEMBL7025618 | 0.76 | PDE3B (0.62) | PDE3AHSD17B10PDE3BMEN1ALDH1A1 | |
| SCHEMBL7030503 | 0.74 | KDM4E (0.50) | PDE3AHSD17B10PDE3BCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-20040167121-A1 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| WO-2004037814-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-0878468-B1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-5994542-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0878468-A1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5756738-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0129258-B1 | IMIDAZOQUINAZOLINE COMPOUND | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-09-23 | — | — | EP | disclosed |
| US-4596806-A | 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one having platelet aggregation inhibitory activity | DAIICHI SEIYAKU CO., LTD. (JP) | 1986-06-24 | — | — | US | disclosed |
| EP-0129258-A1 | Imidazoquinazoline compound | DAIICHI SEIYAKU CO., LTD. (JP) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167121-A1 | Indazolinone compositions useful as kinase inhibitors | LCK, CDK2, CILK1 | PDE3A 3468/4885HSD17B10 2598/4885AR 1155/4885 |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | PDE3A 3478/4885HSD17B10 2651/4885AR 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.